国药现代：关于全资子公司获得药品补充申请批准通知书的公告

Group 1 - The core point of the article is that China National Pharmaceutical Group Modern has announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for a supplemental drug application, allowing for an increase in the specifications of sodium bicarbonate injection and passing the consistency evaluation of generic drug quality and efficacy [2] Group 2 - The approval signifies a regulatory milestone for the company, enhancing its product portfolio and potentially increasing market competitiveness [2] - The sodium bicarbonate injection is expected to meet the growing demand in the pharmaceutical market, reflecting the company's commitment to quality and efficacy in its offerings [2]